###### Strengths and limitations of this study

-   Prepublication of our protocol on PROSPERO ensures methodological transparency and mitigates against potential post-hoc decision making.

-   Study selection, data extraction and quality assessments were conducted independently by two reviewers using standardised forms.

-   We were able to perform meta-analysis to evaluate our primary aims.

-   The generalisability of our evidence is restricted as few studies were identified and all were conducted in high-income countries, with the majority of participants of white ethnicity and aged over 40 years old.

-   Small study numbers also meant we were unable to perform subgroup and sensitivity analyses to evaluate our secondary aims relating to which physical activity interventions/intervention components were most effective.

Introduction {#s1}
============

Physical activity (PA) is associated with important health benefits such as reducing premature mortality and preventing and managing several chronic medical conditions.[@R1] However, more than a quarter of people worldwide fail to meet the guidelines of 150 min of moderate-to-vigorous PA (MVPA) in ≥10 min bouts weekly.[@R3] Physical inactivity costs the UK economy £4.7 billion[@R5] and the US healthcare system US\$117 billion annually.[@R4]

Systematic review evidence indicates that different PA interventions, including pedometer-based[@R6] and individual and group-based interventions,[@R7] increase PA levels in the short term. However, for health benefits, PA needs to be maintained.[@R8] Currently little is known about the long-term sustainability of PA interventions. A meta-analysis,[@R9] which examined the long-term effects of behavioural PA interventions, included only two trials with objective data beyond 12 months[@R10] and more trials with longer-term follow-up and objective PA measurements are needed.[@R9]

Accurate PA assessment is needed to determine the relationship between PA and health and avoid bias and misclassification.[@R13] Subjective self-report PA questionnaires are susceptible to inaccuracy through social desirability,[@R14] recall bias[@R15] or cognitive impairment.[@R16] Directly compared self-reported and objective PA levels have shown considerable discrepancy, with self-reported over-estimating PA.[@R17] Also, when measuring change in PA levels, accelerometry minimises bias and improves precision compared with self-report.[@R19][@R18] Pedometers are popular, simple and low-cost objective measurement devices. Accelerometers can capture both step-counts and time spent in different PA intensities, while remaining blind to participants.[@R20] More trials now measure PA objectively; the proportion of studies using objective PA measures has grown from approximately 4% in 2006 to 71% in 2016.[@R20]

The primary aims were to identify and describe trials in adults with objective PA measures and long-term follow-up (≥12 months) and to determine whether the PA intervention effects varied with follow-up beyond 12 months. Pending sufficient data, secondary aims were to:

-   Determine which interventions are more effective at improving objectively measured PA outcomes beyond 12 months.

-   Evaluate whether, and to what extent, different trial PA components affected adults' overall PA.

-   Identify potential mediators/moderators of PA maintenance.

Methods {#s2}
=======

The protocol for this systematic review was registered with the International Prospective Register of Systematic Reviews. The review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Guidelines.

Search strategy {#s2-1}
---------------

We searched seven databases (Medline, Embase, PsycINFO, Web of Science, Cochrane library, CINAHL and ASSIA) using a combination of three key blocks of terms (PA, objective PA measures and randomised controlled trial, RCT) involving Medical Subject Heading terms and text words ([online supplementary additional file 1 and 2](#SP1){ref-type="supplementary-material"}). Initial search performed September 2017, with updated searches performed April 2018 and December 2019
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We checked reference lists of all primary studies and reviews for additional eligible papers.

Study selection, summary estimates data extraction and risk-of-bias assessments were done independently by two reviewers. Conflicts were resolved via discussion until agreement reached; if necessary a third reviewer was consulted.

Inclusion and exclusion criteria {#s2-2}
--------------------------------

We included RCTs published in English after 01 January 2000. Participants were aged ≥18 years old, healthy, or those 'at risk' of chronic diseases or those with pre-existing chronic medical conditions (either physical or psychological) as expected within a general population. We excluded studies focusing on specific health conditions for example, diabetes, heart disease, etc. We included trials with community-based interventions that objectively measured PA (eg, steps/day, weekly minutes of MVPA) as outcomes, with follow-up beyond 12 months. We excluded trials where control groups received active interventions, including advice about increasing their PA levels ([online supplementary additional file 3](#SP1){ref-type="supplementary-material"}).

Data extraction {#s2-3}
---------------

We imported search results into EndNote V.X7.7.1. After de-duplication, we applied an RCT classifier,[@R21] excluding those with 0%--5% likelihood of being an RCT. Remaining titles and abstracts were screened independently by two of four reviewers (RF/CW and UARC/TH) using a check-list ([online supplementary additional file 4](#SP1){ref-type="supplementary-material"}). Full-texts of potentially relevant studies were assessed independently by the same reviewers. Discrepancies were resolved by discussions, if necessary consulting a third reviewer (TH or DGC as appropriate).

The following data from the nine included studies were extracted independently by RF/CW using a pre-piloted data extraction form: demographic details (age, sex, ethnicity and health status); trial duration and setting; intervention and comparator details; method of outcome measurement; and outcome data.

We contacted three investigators to verify key study characteristics and obtain missing numerical outcome data, obtaining additional unpublished data from two.[@R22] Newman *et al*[@R24] were unable to provide estimated treatment effects at different time points. We did not contact Suguira *et al*[@R25] authors as it was a small study (n=48) conducted 17 years ago. These two latter studies were included in the narrative review.

Quality assessment {#s2-4}
------------------

Two reviewers (from CW/UARC/RK) assessed risk of bias independently for each study using the seven domains outlined in the Cochrane Handbook.[@R26] CW was research assistant on PACE-UP, therefore PACE-UP and PACE-Lift trials[@R27] were independently assessed by RK/UARC. Any disagreements were resolved through discussion with a fourth reviewer (RF).

We judged each domain as either presenting a high, low or unclear risk of bias. A summary is provided ([online supplementary additional file 5](#SP1){ref-type="supplementary-material"}) with supporting quotes and justifications ([online supplementary additional file 6](#SP1){ref-type="supplementary-material"}).

Statistical analysis {#s2-5}
--------------------

We analysed continuous data using change in mean differences (MDs) from baseline in our meta-analyses using Review Manager V. 5.3. We extracted outcomes from all available time points (including prior to 12 months) to examine trends over follow-up. As we anticipated between-study heterogeneity, a random-effects model was used. For trials with multiple relevant arms, we performed necessary adjustments to the data first (eg, splitting the comparator group to avoid double-counting for Harris *et al*[@R27] PACE-UP). Meta-analyses were conducted in Review Manager V. 5.3.

We used the I² statistic to measure statistical heterogeneity among the studies in each analysis; we used the cut offs \<30%, 30%--60%, 61%--75% and \>75% suggesting low, moderate, substantial and considerable heterogeneity, respectively.[@R28]

No intervention effects were seen at 12 months for both Varma 2016 (step-count) and Hays *et al*[@R23] (MVPA). As this review focused on PA maintenance beyond 12 months, these studies were excluded from our final meta-analysis, but included in a sensitivity analysis. We present sensitivity analysis of the total MD in daily steps and weekly MVPA, at the different time points, including and excluding these studies ([online supplementary additional file 7](#SP1){ref-type="supplementary-material"}).

As steps/day and weekly minutes of MVPA are strongly correlated within studies, and outcomes at different time points are also moderately correlated within study, we carried out a single multivariate random-effects meta-analysis using Stata routine mvmeta[@R29] which pooled data from all studies at all time-points for both steps/day and MVPA. The intention was to provide a clearer and more precise overview, taking account of all the data for both outcomes and all time-points. The methods used are described in [online supplementary additional file 8](#SP1){ref-type="supplementary-material"}.

Patient and public involvement {#s2-6}
------------------------------

Patients and the public were not involved in this review.

Results {#s3}
=======

Search results {#s3-1}
--------------

We identified 33 282 records; after de-duplications and using the RCT classifier 16 997 were screened. Two hundred full-text articles were assessed for eligibility, of these 18 records relating to nine unique studies met the inclusion criteria. Five of the nine studies were included in the main meta-analyses and two in sensitivity analyses. [Figure 1](#F1){ref-type="fig"} presents the study selection process flow-chart including reasons for exclusions.

![PRISMA flowchart of literature search results.](bmjopen-2019-034541f01){#F1}

Study characteristics {#s3-2}
---------------------

Details of eligible studies are presented in [table 1](#T1){ref-type="table"}. The nine included RCTs randomly assigned 5832 participants to comparisons of interest. The largest study included 1635 participants, the smallest 48; mean number of participants 648, median number 509.

###### 

Summary of study characteristics

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID               Total N   Age                Participant characteristics          Recruitment pathway   Follow-up time points   Country   Intervention                                                       Intensity and duration of intervention                                                                                                                                          Control                                                                                                              Objective PA device   Outcomes
  ---------------------- --------- ------------------ ------------------------------------ --------------------- ----------------------- --------- ------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- --------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Davies *et al*[@R36]   880       Adults\            At risk of T2D                       Primary care          6 months\               UK        Let's Prevent programme delivered to groups\                       6 hours of training delivered over 1 day or 2 half days. Refreshers sessions delivered at 12 m and 24 m, each lasting 3 hours. Phone calls every 3 m offering ongoing support   Booklet on T2D risk                                                                                                  Pedometer             Objective measure: Steps\
                                   25--75 years old                                                              12 months\                        (focus on weight loss and PA)                                                                                                                                                                                                                                                                                                                                                                 Also measured: Progression to T2DM during 3 years. Lipid levels, HbA1c, medical and medication history, blood pressure, weight, wait and BMI, self-reported physical activity, anxiety, diet, depression, sleep, step count, QOL, change in CV risk.
                                                                                                                 2 years\                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                 3 years                                                                                                                                                                                                                                                                                                                                                                                                                         

  Harris *et al*\        298       Older adults\      --                                   Primary care          3 months\               UK        Pedometer, handbook and diary +4 nurse consultations               Individual 12 week walking programme                                                                                                                                            Usual care from their primary care practice. On trial completion offered individual feedback on PA levels by post.   Accelerometer         Objective measures: Steps, MVPA\
  (PACE-Lift)[@R27]                60--75 years old                                                              12 months\                                                                                                                                                                                                                                                                                                                                                                                                                      Also measured: Anthropometry (BMI, waist circumference, body fat). PROs for example, measuring anxiety, depression and pain. Adverse outcomes (falls, injuries, fractures, CV disease events and deaths)
                                                                                                                 4 years                                                                                                                                                                                                                                                                                                                                                                                                                         

  Harris *et al*\        1023      Adults\            Inactive \<150 mins of MVPA weekly   Primary care          3 months\               UK        Postal group=pedometer, handbook and diary sent in post\           Individual 12 week walking programme                                                                                                                                            Usual care from their primary care practice. On trial completion offered individual feedback on PA levels by post.   Accelerometer         Objective measures: Steps, MVPA\
  (PACE-UP)[@R27]                  45--75 years old                                                              12 months\                        Nurse group=pedometer, handbook and diary +3 nurse consultations                                                                                                                                                                                                                                                                                                                              Also measured: Anthropometry (BMI, waist circumference, body fat). PROs for example, measuring anxiety, depression and pain. Adverse outcomes (falls, injuries, fractures, CV disease events and deaths)
                                                                                                                 3 years                                                                                                                                                                                                                                                                                                                                                                                                                         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI, body mass index; CV, cardiovascular; MVPA, moderate-to-vigorous physical activity; PA, physical activity; PRO, patient reported outcomes; QoL, quality of life.

Four studies were conducted in the UK, four in the USA and one in Japan. Most recruited participants through primary care, two via the community, one did not report their recruitment method. Length of follow-up varied; one study was 18 months, four studies 2 years, three studies 3 years and one study 4 years. Five studies measured PA using ActiGraph accelerometers; one using a Step Activity Monitor accelerometer; and three using pedometers.

Most studies recruited adults aged ≥40 years, three focused on adults aged ≥60 years, three recruited participants at risk of type 2 diabetes mellitus. Three studies recruited participants with low baseline PA: Harris *et al*[@R27] PACE-UP recruited participants self-reporting engaging in \<150 min of MVPA weekly; Suguira *et al*[@R25] recruited participants not engaging in regular exercise; and Pahor *et al*[@R22] recruited 'inactive' participants. Most participants were of white ethnicity. Control groups did not receive specific instructions about increasing their PA levels, but in three studies they received a booklet or handout on type 2 diabetes mellitus risk reduction and in two studies they received educational courses or workshops on successful ageing.

All included studies aimed to increase PA, particularly walking. Harris *et al*[@R27] PACE-UP and Harris *et al*[@R27] PACE-Lift delivered individual level pedometer based-walking programmes and Pahor *et al*[@R22] delivered individualised PA sessions at a centre, as well as home-based activities, whereas five studies delivered group interventions. Varma *et al*[@R31] was a little different in evaluating the effect of volunteering in schools on older adults' walking. Three interventions also included dietary advice.

Intervention length and intensity varied considerably; some were delivered weekly/ fortnightly over a year,[@R22] whereas others had shorter time-frames, for example, 12 weeks in Harris *et al*[@R27] PACE-UP/Harris *et al*[@R27] PACE-Lift. Full intervention details are provided ([table 1](#T1){ref-type="table"}).

Three studies reported step-count and MVPA, four studies step-count only and two MVPA only. Studies reporting MVPA used different counts/minute cut-off points; Harris *et al*[@R27] PACE-UP, Harris *et al*[@R27] PACE-Lift and Yates *et al*[@R32] all defined MVPA as ≥1952 counts/minute whereas Pahor *et al*[@R22] and Hays *et al*[@R23] defined 'moderate PA' as ≥760 counts/min.

Most studies were funded by governmental agencies for example, National Institute for Health Research, National Heart, Lung and Blood Institute.

Risk of bias of included studies {#s3-3}
--------------------------------

Risk of bias judgements are presented in [figures 2 and 3](#F2 F3){ref-type="fig"}. All but one study adequately described the generation of a randomization sequence and were therefore judged to be at low risk of bias in this domain. Suguira *et al*[@R25] was judged to be at high risk, as it was unclear how groups were 'randomly divided'. Allocation concealment was considered low risk for six studies, but unclear for three, due to insufficient detail. All studies were judged to be at high risk of performance bias, as the interventions made blinding unlikely. Hays *et al*[@R23] were judged to have a low risk of bias for participant performance bias, but a high risk for personnel, therefore, we assigned a high overall risk of performance bias. Given the objective outcome measures, seven studies were judged to be at low risk of detection bias, as they measured PA using an accelerometer or sealed pedometer. One study was considered high risk because participants recorded their own step-counts.[@R24] Suguira *et al*[@R25] provided insufficient details and was judged to have an unclear risk. Studies varied in the level of risk of attrition bias. We judged Harris *et al*[@R27] PACE-Lift, Harris *et al*[@R27] PACE-UP, Varma 2016 and Yates *et al*[@R32] to be at low risk: attrition was balanced for each trial arm, reasons for drop-outs were provided and intention-to-treat sensitivity analyses were performed. Suguira *et al*[@R25] was judged to be at high risk of attrition bias due to differential completion between trial arms and not conducting intention-to-treat analysis. The remaining four studies provided insufficient information and had an unclear risk of attrition bias. For eight studies the level of risk of reporting bias was low, for one study (Suguira *et al*[@R25]) the risk was high, as it lacked prospective registration or a published protocol.

![Forest plot showing mean change in daily steps.](bmjopen-2019-034541f02){#F2}

![Forest plot showing mean change in Weekly moderate-to-vigorous physical activity.](bmjopen-2019-034541f03){#F3}

Effects of interventions {#s3-4}
------------------------

Five studies were included in the final meta-analyses. Harris *et al*[@R27] PACE-UP had two intervention arms (nurse and postal), which were presented separately in the meta-analyses.

### Difference in mean change in steps/day {#s3-4-1}

[Figure 2](#F2){ref-type="fig"} shows change in steps/day between intervention and control groups from baseline to all reported time-points for each study. At ≤6 months the pooled estimate of change indicates individuals in the intervention group were doing more steps/day than controls: MD +886 (95% CI: 610 to 1161; I^2^=31%; participants=1878; three studies). At 12 months individuals in the intervention groups were still doing more steps/day than controls: MD +554 (95% CI: 384 to 724; I^2^=0%; participants=2446; four studies). At 2 years only two studies contributed data, the effect estimate was uncertain: MD +290 (95% CI: −7 to 587; I^2^=0%; participants=1126; two studies). However, a positive effect was present at ≥3 years with individuals in the intervention groups doing more steps/day than the controls: MD +494 (95% CI: 251 to 738; I^2^=0%; participants=1944; four studies). Sensitivity analyses including Varma 2016 made little difference to the estimate ([online supplementary additional file 7](#SP1){ref-type="supplementary-material"}).

### Difference in mean change in weekly minutes of MVPA {#s3-4-2}

A similar pattern is seen for mean change in weekly minutes of MVPA ([figure 3](#F3){ref-type="fig"}). At ≤6 months the pooled estimate of change indicates individuals in the intervention group were doing more minutes of weekly MVPA than controls: MD +51 (95% CI: 40 to 62; I^2^=34%; participants=2079; three studies). At 12 months individuals in the intervention groups were still doing more minutes of weekly MVPA than controls: MD +35 (95% CI: 27 to 43; I^2^=0%; participants=2547; four studies). This effect was sustained at 2 years: MD +26 (95% CI: 3 to 49; I^2^=69%; participants=1254; two studies). At 2 years substantial between study heterogeneity was detected, however the test's accuracy is impaired by the small number of studies (n=2) reporting data. There was also a sustained effect at ≥3 years with intervention group participants doing more minutes of weekly MVPA than controls: MD +25 (95% CI: 13 to 37; I^2^=0%; participants=1458; three studies). Sensitivity analyses including Hays *et al*[@R23] attenuated the effect, but left the pattern and conclusions unchanged ([online supplementary file 1](#SP1){ref-type="supplementary-material"}).

[Figures 4 and 5](#F4 F5){ref-type="fig"} demonstrate very clearly the consistency of effect over time within each study both for steps ([figure 4](#F4){ref-type="fig"}) and MVPA ([figure 5](#F5){ref-type="fig"}). This consistency is reinforced by the multivariate meta-analysis ([online supplementary additional file 8](#SP1){ref-type="supplementary-material"}), where MVPA estimates are essentially unchanged, but confidence limits are narrower. For steps/day the estimates were largely similar to the univariate meta-analyses, the notable change being the estimate at 2 years (based on only two studies) which increased from 290 (−7 to 587) in the univariate analysis, to 479 (244 to 715) in the multivariate; again, confidence limits were narrower.

![Graph showing individual study data demonstrating mean change in daily steps overtime.](bmjopen-2019-034541f04){#F4}

![Graph showing individual study data demonstrating mean change in weekly MVPA overtime. MVPA, moderate-to-vigorous physical activity.](bmjopen-2019-034541f05){#F5}

### Effects of interventions not included in the main meta-analysis {#s3-4-3}

Two trials not included in the main meta-analyses, due to data availability, both showed intervention effects beyond 12 months, that is, consistent with meta-analysis findings. Suguira *et al*[@R25] found that a 2 year intervention increased mean daily steps in the exercise group compared with the control group (6800--8500 vs 5700--6800 respectively, p\<0.01). Newman *et al*[@R24] reported that after 18 months the lifestyle intervention group increased their median daily steps compared with controls (8499 vs 6462 respectively, p\<0.0001).

Discussion {#s4}
==========

Statement of principal findings {#s4-1}
-------------------------------

The review aimed to identify and describe RCTs of PA interventions that measured PA levels objectively and had follow-up beyond 12 months. We adhered to PRISMA guidance throughout the process. Because of the small number of trials identified we were unable to use meta-regression to explore which types of intervention were more successful. Nevertheless, the included studies provided evidence of sustained PA intervention effects beyond 12 months and up to 4 years for both steps (increase of +494 steps/day) and MVPA (increase of +25 min of MVPA weekly) from both individual and group-based PA interventions. The multivariate meta-analysis emphasised the consistency of step-count and MVPA results.

Strengths and weaknesses of the study {#s4-2}
-------------------------------------

This review has both strengths and limitations. It was carried out as presented in the prepublished protocol, but due to the small number of studies included, we were unable to perform subgroup and sensitivity analyses to evaluate our secondary aims. Two reviewers independently screened papers at the title, abstract and full-text level and assessed each study for risk of bias. Blinding of participants and personnel is not achievable in interventions of this type, which exposes the trials to a risk of performance bias; although objective outcome measurement mitigates the risk of bias overall. While not all studies clearly described their randomisation or allocation methods, participant attrition or performed an intention to treat analysis, overall the methodological quality of included studies was good. Due to the limited number of studies identified in this review, the generalisability of our evidence is restricted. All included studies were conducted in high-income countries and the majority of participants were of white ethnicity and aged over 40 years old. The interventions varied in their intensity and how pragmatic they would be to implement in real-world settings. Our use of multivariate meta-analysis is an important innovation, allowing us to incorporate data on different outcomes (steps and MVPA) and different time points in a single model improving precision of estimates. With the addition of more studies it could easily be extended to multivariate meta-regression.

Comparison of our findings with other studies {#s4-3}
---------------------------------------------

Several reviews have explored PA maintenance; however, to our knowledge, ours is the first to focus solely on objective PA outcomes beyond 12 months. One systematic review[@R9] explored whether behavioural interventions increased PA at 12--36 months in 55--70 year olds; but only 2 of the 21 studies objectively measured PA levels.[@R10] Kuller *et al*[@R10] are included in our review as Newman *et al*.[@R24] We excluded Opdenacker *et al*[@R11] due to randomization concerns. Consistent with our findings, this review found that behavioural interventions led to long-term PA improvements at 12 months.[@R9] However, they found little evidence for significant intervention effects beyond 12 months and concluded PA maintenance was unclear.[@R9] Two recent reviews looked at the effectiveness of PA interventions in achieving behaviour change and maintenance, in healthy inactive adults[@R7] and in young and middle-aged adults.[@R33] They found clear evidence that PA interventions were effective at maintaining behaviour change after 6 months or more[@R7] with interventions having a larger effect on maintenance at 6--9 months compared with 9--15 months.[@R33] However, beyond 15 months there was little evidence. The majority of the papers in these two reviews used subjective PA measurements and had follow-up ≤12 months. Our paper builds on and extends findings from all three reviews by identifying more studies with objective PA measures beyond 12 months, and evidence of sustained PA intervention effects up to 4 years.

Implications for clinicians and policy makers {#s4-4}
---------------------------------------------

Our review has important clinical and policy implications. An increase of approximately 35 min of MVPA weekly at 1 year and approximately 25 min by 3--4 years, would contribute substantially towards helping participants meet national PA recommendations of 150 min of MVPA weekly. Additionally, the greatest health benefits accrue by increasing PA levels in those with very low PA levels, especially if that activity is of moderate or vigorous intensity.[@R34] The sustained effect on PA beyond 12 months could therefore produce important long-term health benefits and suggests that investing in community-based PA interventions that achieve long-term effects, would be worthwhile for practitioners and commissioners. Due to insufficient data we cannot be sure exactly what interventions are most effective for which participants; however, our findings are based on both individual pedometer-based walking interventions,[@R27] individual PA sessions delivered at a centre, supported by home-based activities[@R22] and group-based PA interventions.[@R23]

Future research and unanswered questions {#s4-5}
----------------------------------------

Our review also has important implications for future research. 'Maintenance of PA' is used and defined in different ways.[@R37] A standard definition of PA maintenance would progress understanding of this area. Studies often use different counts/minute cut-points to define MVPA (Harris *et al*[@R27] PACE-UP; Harris *et al*[@R27] PACE-Lift; Pahor *et al*[@R22]; Yates *et al*[@R32]). Implementing a consistent cut-point would allow for more accurate comparison of results between studies. Given that PA requires regular performance in order to achieve long-term health benefits, future research into PA interventions should be designed with maintenance in mind, for example, by considering potential follow-up time-points, maximising participant engagement to reduce attrition and utilising specific behaviour change techniques promoting long-term habit formation.[@R7] The lack of trials with objective PA data beyond 12 months limits our ability to comment on which types of interventions and specifically which intervention components were most likely to achieve long-term behaviour change. More large-scale pragmatic trials in real-world settings with long-term objective PA measures are needed. An increasing number of studies are now objectively measuring PA levels.[@R20] It would therefore be beneficial to update this review and meta-analysis when more trials with long-term data are available.

Conclusions {#s5}
===========

There are currently few PA interventions with objective follow-up beyond 12 months. Nevertheless, the studies included in this review provide convincing evidence that, where studies demonstrated short term effects, there were sustained PA intervention effects beyond 12 months and up to 4 years for both steps/day and weekly MVPA. This is an important positive message for tackling the public health inactivity challenge.
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